RE:RE:RE:RE:RE:“Second mouse gets the cheese “Cancer biopharma IPOs build momentum of the heels of CG Oncology's offering
Cancer-focused Arrivent Biopharma announced late Thursday that it is looking at around $175 million in gross proceeds from its upsized initial public offering.
Goldman Sachs, Jefferies and Citigroup are joint book-running managers for ArriVent’s IPO, while LifeSci Capital is its lead manager.
https://www.biospace.com/article/arrivent-s-175m-upsized-ipo-builds-momentum-on-heels-of-cg-oncology-offering/